WEBINAR: Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay – 28 June 2023

cnb825 webinar promo v1 |
Learn more
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

      View all news

      Upcoming Events

      • ISSX DMDG 2023

      • MPS World Summit Berlin 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Chat live with an expert

CN Bio to bring 10 organs together on a chip

February 28, 2019 by CN Bio

London Organ-­on-­Chip specialist CN Bio today announced it has secured an exclusive license to technology from the Massachusetts Institute of Technology for Organ-­on-­Chip systems which connect human tissues from up to 10 organs.

CN Bio participated with MIT on a US$26M DARPA federal contract to develop a Human-­Body-­on-­Chip system. In an article published in Nature Scientific Reports in March 2018, MIT researchers and CN Bio announced the successful final milestone of this program to bring 10 organs together on a chip.

CN Bio CEO Dr David Hughes said:

Scientists currently lack adequate means to determine whether a new drug to treat one organ is likely to have adverse effects on another. At present much of this information comes from poorly predictive animal studies. Many costly drug failures take place because we lack the ability to generate human relevant data in the laboratory – this is exactly the data which our PhysioMimix Multi­-Organ­-on-­Chip studies will provide.

These MIT patents extend our portfolio to cover multi­organ systems. We believe multi­organ safety and efficacy studies can bridge a serious gap in drug development between simple preclinical in vitro tests and difficult and expensive animal testing.

By recreating human organ interactions on CN Bio’s smart­phone sized chip, scientists can measure the effects of drugs or other chemicals on different tissues of the body.

The CN Bio team is building the multi­organ consumable plates to be compatible with its award-winning PhysioMimix benchtop Organ-­on-­Chip system.

PhysioMimix is a printer­sized device with open­-well plates where micro-tissues that mimic the structure and function of human organs and tissues can be cultured. Linking two or more of these miniature systems using microfluidics means multiple organs interact and respond to stimuli.

Launched in May 2018, PhysioMimix is being used by pharmaceutical and consumer goods companies globally and by the US Food and Drug Administration (FDA) to conduct Organ-­on-­Chip assays.

Scientists use the device to culture micro­tissues that mimic the structure and function of human organs and run a wide range of assays and experiments. These provide essential data on how a new drug, food additive, cosmetic or chemical will affect the key organs in our bodies.

The multi­organ patents have been licensed from the MIT School of Biological Engineering, laboratory of Professor Linda Griffith.

CN Bio expects multi­organ consumable plates for PhysioMimix system to be available later in 2019. Early multi-­organ studies will provide data on how
drugs and chemicals interact within a gut­-liver or lung-­liver systems, two in-demand models for understanding drug metabolism and therapeutic safety respectively.

Category iconPress releases

Primary Sidebar

Other recent news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023
  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility | Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023

Upcoming events

ISSX DMDG 2023 June 11-14, 2023

MPS World Summit Berlin 2023 June 26-30, 2023